# Deepcell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/deepcell

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: www.deepcell.com
- Total disclosed funding: $87M
- Latest round: Series B (Jan 6, 2022)
- Investors on record: 9

## About

Deepcell, Inc. specializes in advanced single-cell analysis, leveraging innovative technologies to provide essential insights for researchers in various scientific fields, including cancer research and cell therapy.Founded in 2017, Deepcell, Inc. operates out of Menlo Park, US, focusing on single-cell analysis through its REM-I platform. The company has conducted three funding rounds, with the latest being a Series B round on January 6, 2022, raising USD 62.82 mn, led by Koch Disruptive Technologies and joined by other notable investors. The founders include Euan Ashley, Maddison Masaeli, and Mahyar Salek, with Maddison Masaeli serving as the CEO.Deepcell, Inc. is primarily focused on advancing single-cell analysis through its flagship product, the REM-I platform. This platform integrates label-free imaging, deep learning, and gentle sorting technologies to deliver comprehensive analysis of cell morphology, which is crucial for understanding cell phenotype and function. The REM-I platform is utilized by researchers in fields such as cancer research, developmental biology, and cell and gene therapy, enabling real-time characterization of single cells. Deepcell targets academic institutions, biotechnology firms, and pharmaceutical organizations across North America, Europe, and Asia.Deepcell's revenue model centers on the sale of the REM-I platform and its associated consumables. Transactions are primarily conducted through direct sales to research institutions and commercial laboratories, allowing clients to purchase the REM-I instruments and necessary consumables for their studies. The company also offers access to the Axon data suite, facilitating the storage, visualization, and analysis of high-dimensional cell morphology data, thus enhancing clients' research capabilities in single-cell analysis.In January 2022, Deepcell, Inc. secured USD 62.82 mn during its Series B funding round, led by Koch Disruptive Technologies. The company plans to utilize this funding to accelerate growth, enhance its platform, and support commercialization efforts. Future initiatives may include developing new products and expanding into additional markets, although specific products and timelines have not been disclosed.

## Funding rounds

- Series B, Jan 6, 2022, $63M — Andreessen Horowitz, Casdin Capital, Horizons Ventures, Bow Capital, Koch Disruptive Technologies, Bridger Healthcare
- Series A, Dec 7, 2020, $20M — Andreessen Horowitz, Stanford University, DCVC, Bow Capital, Fifty Years
- Seed, Dec 15, 2017, $4M — Andreessen Horowitz, Stanford University, DCVC, Fifty Years

## Investors

- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Seed, Series A, Series B
- Stanford University — Seed, Series A
- DCVC (https://capitalatlas.ai/funds/dcvc) — Seed, Series A
- Fifty Years (https://capitalatlas.ai/funds/fifty-years) — Seed, Series A
- Bow Capital (https://capitalatlas.ai/funds/bow-capital) — Series A, Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Horizons Ventures — Series B
- Koch Disruptive Technologies (https://capitalatlas.ai/funds/koch-disruptive-technologies) — Series B
- Bridger Healthcare — Series B